Trial · NCT04925375
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
NCT04925375, Phase 2, Recruiting, Children's Hospital Medical Center, Cincinnati
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease. Trials, record NCT04925375. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04925375
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
- NCT number
- NCT04925375
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 38 participants, estimated
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Conditions
- Interstitial Lung Disease, Common Variable Immunodeficiency
- Interventions
- Abatacept, Placebo
- First posted
- 2021-06-14
- Last updated
- 2026-07-22
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | High Resolution CT Scan of the chest (HRCT) | 6 months | Proportion of subjects achieving a significant response (defined as \>30 percent change in lung tissue disease burden by GLILD) on HRCT after 6 months of abatacept therapy. |
| Secondary | Forced vital capacity (FVC) | 6 months, 12 months | Forced vital capacity (FVC) |
| Secondary | Forced expiratory volume (FEV) | 6 months, 12 months | Forced expiratory volume (FEV) |
| Secondary | Diffusion capacity of carbon monoxide (DLCo) | 6 months, 12 months | Diffusion capacity of carbon monoxide (DLCo) |
| Secondary | Incidence | 6 months, 12 months | Incidence of new onset autoimmune/inflammatory diseases while on abatacept or placebo |
| Secondary | Resolution | 6 months, 12 months | Resolution of existing autoimmune/inflammatory diseases while on abatacept or placebo |
| Secondary | Change in Short Form-36 scores | 6 months, 12 months | Short Form-36: scoring ranges from 0-100 where a higher score denotes better health |
| Secondary | Change in PedsQL (Pediatric Quality of Life) Generic Core scores | 6 months, 12 months | PedsQL Generic Core Scales: items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL. Range of 0-2300 for ages above 4, range of 0-2100 for 4 years old |
| Secondary | Change in King's Interstitial Lung Disease scores | 6 months, 12 months | King's Interstitial Lung Disease: scoring ranges from 0-100 where a higher score denotes better health |
| Secondary | Steroid usage | 6months, 12 months | Cumulative number of steroids used after 6 months and 12 months |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01FD007267 | Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) IND #152820 9/2/20 | JORDAN, MICHAEL | CINCINNATI CHILDRENS HOSP MED CTR | FOOD AND DRUG ADMINISTRATION | 2021 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04925375
GET https://conductscience.org/api/trials/v1/NCT04925375/registered